Biotech

Vivus: FDA Panel Live Blog

By Adam Feuerstein

• Tickers in this article:
• VVUS
• ARNA
• OREX

TheStreet's biotech columnist Adam Feuerstein is providing live coverage of the FDA advisory panel reviewing Vivus' obesity pill Qnexa.

02/22/12 - 03:41 PM EST

TheStreet Ratings Top 10 Rating Changes

By Kevin Baker

• Tickers in this article:
• SU
• DVN
• XRX
• CCJ
• REGN
• CPN

TheStreet Ratings released rating changes on 106 U.S. common stocks for week ending February 17, 2012. 83 stocks were upgraded and 23 stocks were downgraded by our stock model.

02/21/12 - 01:55 PM EST

Threshold Drug Delays Pancreatic Cancer

By Adam Feuerstein

• Tickers in this article:
• THLD
• CELG
• INFI
• CLVS

Threshold reports positive results from a mid-stage study of its pancreatic cancer drug TH-302.

02/21/12 - 01:51 PM EST

A Negative Vote for Vivus Obesity Drug, Says 'FDA Panel Whisperer'

By Adam Feuerstein

• Tickers in this article:
• VVUS
• ARNA
• OREX

An analysis of experts' past voting records shows Vivus faces a stiff test Wednesday from an FDA panel reviewing the obesity drug Qnexa.

02/21/12 - 10:39 AM EST

Corcept Has Upside Following Drug Approval

By Adam Feuerstein

• Tickers in this article:
• CORT

FDA approved Corcept's Korlym for Cushing's syndrome.

02/21/12 - 12:54 PM EST

The Case for Shorting Elan Into Upcoming Alzheimer's Trial Results

By Nathan Sadeghi-Nejad

• Tickers in this article:
• ELN
• PFE
• JNJ
• LLY

The amyloid beta hypothesis doesn't explain Alzheimer's, which leaves Elan and its partners in trouble.

02/21/12 - 07:00 AM EST

Dion's Friday ETF Winners and Losers

By Don Dion

• Tickers in this article:
• GAZ
• KWT
• KCE
• JJC
• XBI
• GDXJ

The natural gas ETFs are up today following a favorable inventory report.

02/17/12 - 02:50 PM EST

Gilead Suffers First Hep C Drug Setback

By Adam Feuerstein

• Tickers in this article:
• GILD
• IDIC
• VRTX
• BMY

Gilead's GS-7977 fails to cure hard-to-treat hepatitis C patients, showing the wonder drug has flaws.

02/17/12 - 10:46 AM EST

Biotech Stock Mailbag: Vivus, Chelsea, BioCryst

By Adam Feuerstein

• Tickers in this article:
• VVUS
• CHTP
• BCRX
• BPAX
• EXEL
• KERX

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

02/17/12 - 05:30 AM EST

Idenix Pharmaceuticals Is Looking For Partners

By Alexandra Zendrian

• Tickers in this article:
• IDIX

CEO Ronald Renaud Jr. discusses getting one of his company's drugs into a combination study and the possibility of being acquired.

02/16/12 - 03:06 PM EST

These Drugs Stocks Will Win FDA Approval

By Adam Feuerstein

• Tickers in this article:
• CORT
• DSCO
• AFFY
• CHTP
• VVUS
• CBRX

Contestants in TheStreet's FDA Drug-Approval Contest forecast their winners and losers.

02/16/12 - 12:04 PM EST

BioSante: A Penny Stock Still Overvalued

By Adam Feuerstein

• Tickers in this article:
• BPAX
• ABT
• AUXL
• ENDP
• WPI
• LLY

Day traders are propping up BioSante's valuation. At some point, the numbers start to matter.

02/16/12 - 07:15 AM EST